Selected-GenAtlas references SOURCE GeneCards NCBI Gene Swiss-Prot Ensembl
HGNC UniGene Nucleotide OMIM UCSC
Home Page
FLASH GENE
Symbol CDKN3 contributors: mct - updated : 14-04-2014
HGNC name cyclin-dependent kinase inhibitor 3 (CDK2-associated dual specificity phosphatase)
HGNC id 1791
DNA
TYPE functioning gene
STRUCTURE 23.28 kb     8 Exon(s)
10 Kb 5' upstream gene genomic sequence study
MAPPING cloned Y linked   status provisional
RNA
TRANSCRIPTS type messenger
identificationnb exonstypebpproduct
ProteinkDaAAspecific expressionYearPubmed
8 - 906 - 212 - 2013 2377519
7 - 786 - 172 - 2013 2377519
EXPRESSION
Type widely
   expressed in (based on citations)
organ(s)
SystemOrgan level 1Organ level 2Organ level 3Organ level 4LevelPubmedSpeciesStageRna symbol
Digestiveintestinelarge intestinecolon  
 intestinesmall intestine   
Lymphoid/Immunelymph node    
tissue
SystemTissueTissue level 1Tissue level 2LevelPubmedSpeciesStageRna symbol
Connectivebone   
cell lineage
cell lines
fluid/secretion
at STAGE
cell cycle     cell cycle, G1, S, checkpoint
PROTEIN
PHYSICAL PROPERTIES
STRUCTURE
motifs/domains
HOMOLOGY
Homologene
FAMILY
  • CDK inhibitor family
  • protein-tyrosine phosphatase family
  • CATEGORY enzyme , protooncogene
    SUBCELLULAR LOCALIZATION     intracellular
    intracellular,cytoplasm
    basic FUNCTION
  • cyclin dependent kinases CDC2 (CDK1) and CDK2 (CDC2/CDK2) inhibitor, may be playing a role in cell cycle regulation
  • has a dual function in cell cycling, and acts as an oncogene in hepatocellular carcinoma
  • is essential for normal mitosis and G1/S transition
  • controls mitosis through the CDK1 signaling axis
  • CELLULAR PROCESS cell cycle
    cell life, proliferation/growth
    PHYSIOLOGICAL PROCESS
    text negative control
    PATHWAY
    metabolism
    signaling
    a component stable complex with CDK2
    INTERACTION
    DNA
    RNA
    small molecule
    protein
  • dephosphorylates threonine-161 of CDK1 during mitotic exit
  • binds and activates ROCK2 (RNA-mediated downregulation of CDKN3 leads to decreased ROCK2 activity and this, in turn, increases RAC1-mediated invasion)
  • cell & other
    REGULATION
    ASSOCIATED DISORDERS
    corresponding disease(s)
    Susceptibility
    Variant & Polymorphism
    Candidate gene
    Marker
  • may be used as a novel tumor marker to predict the prognosis of epithelial ovarian cancer (EOC)
  • Therapy target
    SystemTypeDisorderPubmed
    cancerdigestiveliver
    antagonism of CDKN3 may be of interest for the treatment of hepatocellular carcinoma
    ANIMAL & CELL MODELS